计划状态
活跃，非招募阶段
第 1 阶段允许先接受免疫治疗
是CRC 指导的试验
是药物
Atezolizumab, Cabozantinib标签
MSS/ MMRp| 地点 | 位置状态 |
|---|---|
| 美国 | |
|
Exelixis Clinical Site #53 亚利桑那州吉尔伯特 85234 |
活跃，非招募 |
|
Exelixis Clinical Site #18 亚利桑那州凤凰城 85054 |
活跃，非招募 |
|
Exelixis Clinical Site #1 加利福尼亚州杜阿尔特 91010 |
活跃，非招募 |
|
Exelixis Clinical Site #20 La Jolla, California 92090 |
活跃，非招募 |
|
Exelixis Clinical Site #46 加利福尼亚州洛杉矶 90025 |
活跃，非招募 |
|
Exelixis Clinical Site #51 加利福尼亚州纽波特海滩 92663 |
活跃，非招募 |
|
Exelixis Clinical Site #62 Santa Monica, California 90404 |
活跃，非招募 |
|
Exelixis Clinical Site #21 Stanford, California 94305 |
活跃，非招募 |
|
Exelixis Clinical Site #34 科罗拉多州丹佛 80218 |
活跃，非招募 |
|
Exelixis Clinical Site #50 科罗拉多州丹佛 80218 |
活跃，非招募 |
|
Exelixis Clinical Site #42 New Haven, Connecticut 06511 |
活跃，非招募 |
|
Exelixis Clinical Site #48 哥伦比亚特区华盛顿 20007 |
活跃，非招募 |
|
Exelixis Clinical Site #16 佛罗里达州杰克逊维尔 32224 |
活跃，非招募 |
|
Exelixis Clinical Site #76 佛罗里达州坦帕市 33612 |
活跃，非招募 |
|
Exelixis Clinical Site #60 Atlanta, Georgia 30318 |
活跃，非招募 |
|
Exelixis Clinical Site #79 Atlanta, Georgia 30341 |
活跃，非招募 |
|
Exelixis Clinical Site #32 Harvey, Illinois 60426 |
活跃，非招募 |
|
Exelixis Clinical Site #23 Fairway, Kansas 66205 |
活跃，非招募 |
|
Exelixis Clinical Site #57 肯塔基州列克星敦 40536 |
活跃，非招募 |
|
Exelixis Clinical Site #24 New Orleans, Louisiana 70112 |
活跃，非招募 |
|
Exelixis Clinical Site #10 马萨诸塞州波士顿 02215 |
活跃，非招募 |
|
Exelixis Clinical Site #3 密歇根州底特律 48201 |
活跃，非招募 |
|
Exelixis Clinical Site #17 明尼苏达州罗切斯特 55905 |
活跃，非招募 |
|
Exelixis Clinical Site #65 密苏里州玻利瓦尔 65613 |
活跃，非招募 |
|
Exelixis Clinical Site #43 Kansas City, Missouri 64111 |
活跃，非招募 |
|
Exelixis Clinical Site #35 内布拉斯加州奥马哈 68130 |
活跃，非招募 |
|
Exelixis Clinical Site #59 内布拉斯加州奥马哈 68130 |
活跃，非招募 |
|
Exelixis Clinical Site #61 内华达州拉斯维加斯 89169 |
活跃，非招募 |
|
Exelixis Clinical Site #38 新泽西州卡姆登 08103 |
活跃，非招募 |
|
Exelixis Clinical Site #27 East Brunswick, New Jersey 08816 |
活跃，非招募 |
|
Exelixis Clinical Site #31 新泽西州新不伦瑞克 08903 |
活跃，非招募 |
|
Exelixis Clinical Site #37 纽约州布朗克斯 10461 |
活跃，非招募 |
|
Exelixis Clinical Site #40 East Setauket, New York 11733 |
活跃，非招募 |
|
Exelixis Clinical Site #11 纽约州纽约市 10029 |
活跃，非招募 |
|
Exelixis Clinical Site #67 俄亥俄州克利夫兰 44195 |
活跃，非招募 |
|
Exelixis Clinical Site #49 俄亥俄州哥伦布市 43210 |
活跃，非招募 |
|
Exelixis Clinical Site #64 Kettering, Ohio 45409 |
活跃，非招募 |
|
Exelixis Clinical Site #71 俄克拉荷马州俄克拉荷马城 73104 |
活跃，非招募 |
|
Exelixis Clinical Site #6 Oklahoma City, Oklahoma 73120 |
活跃，非招募 |
|
Exelixis Clinical Site #102 俄勒冈州波特兰 97213 |
活跃，非招募 |
|
Exelixis Clinical Site #45 俄勒冈州波特兰 97239 |
活跃，非招募 |
|
Exelixis Clinical Site #41 Bethlehem, Pennsylvania 18015 |
活跃，非招募 |
|
Exelixis Clinical Site #15 宾夕法尼亚州费城 19107 |
活跃，非招募 |
|
Exelixis Clinical Site #55 Philadelphia, Pennsylvania 19111 |
活跃，非招募 |
|
Exelixis Clinical Site #66 宾夕法尼亚州匹兹堡 15232 |
活跃，非招募 |
|
Exelixis Clinical Site #95 南卡罗来纳州查尔斯顿 29414 |
活跃，非招募 |
|
Exelixis Clinical Site #13 德克萨斯州达拉斯 75246 |
活跃，非招募 |
|
Exelixis Clinical Site #26 德克萨斯州达拉斯 75390 |
活跃，非招募 |
|
Exelixis Clinical Site #114 德克萨斯州沃斯堡 76104 |
活跃，非招募 |
|
Exelixis Clinical Site #29 德克萨斯州休斯顿 77030 |
活跃，非招募 |
|
Exelixis Clinical Site #39 德克萨斯州休斯顿 77030 |
活跃，非招募 |
|
Exelixis Clinical Site #44 德克萨斯州休斯顿 77030 |
活跃，非招募 |
|
Exelixis Clinical Site #33 Lubbock, Texas 79410 |
活跃，非招募 |
|
Exelixis Clinical Site #63 德克萨斯州圣安东尼奥 78229 |
活跃，非招募 |
|
Exelixis Clinical Site #2 犹他州盐湖城 84112 |
活跃，非招募 |
|
Exelixis Clinical Site #30 Blacksburg, Virginia 24060 |
活跃，非招募 |
|
Exelixis Clinical Site #14 Charlottesville, Virginia 22908 |
活跃，非招募 |
| 澳大利亚 | |
|
Exelixis Clinical Site #98 Albury, New South Wales 2640 |
活跃，非招募 |
|
Exelixis Clinical Site #101 新南威尔士州坎珀当 2050 |
活跃，非招募 |
|
Exelixis Clinical Site #115 Gosford, New South Wales 2250 |
活跃，非招募 |
|
Exelixis Clinical Site #112 North Ryde, New South Wales 2109 |
活跃，非招募 |
|
Exelixis Clinical Site #123 新南威尔士州兰德威克 2031 |
活跃，非招募 |
|
Exelixis Clinical Site #99 St Albans, Victoria 3021 |
活跃，非招募 |
| 比利时 | |
|
Exelixis Clinical Site #52 根特 9000 |
活跃，非招募 |
|
Exelixis Clinical Site #54 鲁汶 3000 |
活跃，非招募 |
| 法国 | |
|
Exelixis Clinical Site #88 La Roche-sur-Yon, Cedex 9 85925 |
活跃，非招募 |
|
Exelixis Clinical Site #8 Villejuif, Cedex 94805 |
活跃，非招募 |
|
Exelixis Clinical Site #92 波尔多 33076 |
活跃，非招募 |
|
Exelixis Clinical Site #93 Brest 29229 |
活跃，非招募 |
|
Exelixis Clinical Site #87 CAEN Cedex 05 14076 |
活跃，非招募 |
|
Exelixis Clinical Site #69 Le Mans 72000 |
活跃，非招募 |
|
Exelixis Clinical Site #97 Lille 59000 |
活跃，非招募 |
|
Exelixis Clinical Site #89 Lyon Cedex 08 69373 |
活跃，非招募 |
|
Exelixis Clinical Site #109 Marseille 13273 |
活跃，非招募 |
|
Exelixis Clinical Site #104 Nice Cedex 02 06189 |
活跃，非招募 |
|
Exelixis Clinical Site #80 Nîmes Cedex 09 30029 |
活跃，非招募 |
|
Exelixis Clinical Site #78 Paris 75005 |
活跃，非招募 |
|
Exelixis Clinical Site #7 巴黎 75010 |
活跃，非招募 |
|
Exelixis Clinical Site #68 Paris 75013 |
活跃，非招募 |
|
Exelixis Clinical Site #72 巴黎 75015 |
活跃，非招募 |
|
Exelixis Clinical Site #82 Saint-Grégoire 35760 |
活跃，非招募 |
|
Exelixis Clinical Site #119 Strasbourg 67000 |
活跃，非招募 |
|
Exelixis Clinical Site #107 Suresnes 92150 |
活跃，非招募 |
|
Exelixis Clinical Site #105 Vandoeuvre les nancy 54519 |
活跃，非招募 |
| 德国 | |
|
Exelixis Clinical Site #56 Düsseldorf, Nordrhein-Westfalen 40225 |
活跃，非招募 |
|
Exelixis Clinical Site #36 图宾根 72076 |
活跃，非招募 |
| 意大利 | |
|
Exelixis Clinical Site #84 Meldola, FC 47014 |
活跃，非招募 |
|
Exelixis Clinical Site #47 Rozzano, Milano 20089 |
活跃，非招募 |
|
Exelixis Clinical Site #108 米兰 20132 |
活跃，非招募 |
|
Exelixis Clinical Site #103 米兰 20133 |
活跃，非招募 |
|
Exelixis Clinical Site #25 米兰 20133 |
活跃，非招募 |
|
Exelixis Clinical Site #4 米兰 20133 |
活跃，非招募 |
|
Exelixis Clinical Site #85 那不勒斯 80131 |
活跃，非招募 |
|
Exelixis Clinical Site #121 Pavia 27100 |
活跃，非招募 |
|
Exelixis Clinical Site #110 罗马 00168 |
活跃，非招募 |
| 荷兰 | |
|
Exelixis Clinical Site #12 Nijmegen, Gelderland 6525 GA |
活跃，非招募 |
| 西班牙 | |
|
Exelixis Clinical Site #74 Santiago De Compostela, A Coruña 15706 |
活跃，非招募 |
|
Exelixis Clinical Site #91 Elche, Alicante 03203 |
活跃，非招募 |
|
Exelixis Clinical Site #94 Oviedo, Asturias 33011 |
活跃，非招募 |
|
Exelixis Clinical Site #70 Palma De Mallorca, Baleares 07120 / 07010 |
活跃，非招募 |
|
Exelixis Clinical Site #113 Badalona, Barcelona 08916 |
活跃，非招募 |
|
Exelixis Clinical Site #116 Sabadell, Barcelona 08208 |
活跃，非招募 |
|
Exelixis Clinical Site #96 Jeréz De La Frontera, Cádiz 11407 |
活跃，非招募 |
|
Exelixis Clinical Site #90 纳瓦拉潘普洛纳 31008 |
活跃，非招募 |
|
Exelixis Clinical Site #117 La Laguna, Santa Cruz De Tenerife 38320 |
活跃，非招募 |
|
Exelixis Clinical Site #75 巴塞罗那 08003 |
活跃，非招募 |
|
Exelixis Clinical Site #58 Barcelona 08022 |
活跃，非招募 |
|
Exelixis Clinical Site #83 Barcelona 08023 |
活跃，非招募 |
|
Exelixis Clinical Site #86 Barcelona 08025 |
活跃，非招募 |
|
Exelixis Clinical Site #28 巴塞罗那 08035 |
活跃，非招募 |
|
Exelixis Clinical Site #9 巴塞罗那 08035 |
活跃，非招募 |
|
Exelixis Clinical Site #73 Barcelona 08036 |
活跃，非招募 |
|
Exelixis Clinical Site #118 Girona 17007 |
活跃，非招募 |
|
Exelixis Clinical Site #77 马德里 28034 |
活跃，非招募 |
|
Exelixis Clinical Site #106 马德里 28040 |
活跃，非招募 |
|
Exelixis Clinical Site #111 马德里 28040 |
活跃，非招募 |
|
Exelixis Clinical Site #22 马德里 28041 |
活跃，非招募 |
|
Exelixis Clinical Site #5 马德里 28041 |
活跃，非招募 |
|
Exelixis Clinical Site #81 马德里 28046 |
活跃，非招募 |
|
Exelixis Clinical Site #100 Málaga 29010 |
活跃，非招募 |
| 英国 | |
|
Exelixis Clinical Site #122 Middlesex, England HA6 2RN |
活跃，非招募 |
|
Exelixis Clinical Site #120 Preston, England PR2 9HT |
活跃，非招募 |
|
Exelixis Clinical Site #124 Cardiff, Wales CF14 2TL |
活跃，非招募 |
|
Exelixis Clinical Site #19 London EC1M 6BQ |
活跃，非招募 |
纳入标准
纳入标准
Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent:
Dose-Escalation Stage:
Subjects with UC (including renal pelvis, ureter, bladder, urethra) after prior platinum-based therapy, or
Subjects with RCC (clear cell, non-clear cell histology) with or without prior systemic anticancer therapy
Expansion Stage:
Inoperable locally advanced or metastatic solid tumor (UC, RCC, CRPC, NSCLC, TNBC, OC, EC, HCC, GC/GEJC/LEC, CRC, H&N cancer, and DTC as outlined above)
Measurable disease per RECIST 1.1 as determined by the investigator.
Tumor tissue material available (archival or recent tumor biopsy)
Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
Age eighteen years or older on the day of consent.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Adequate organ and marrow function.
Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.
Female subjects of childbearing potential must not be pregnant at screening.
排除标准
排除标准：
Prior treatment with cabozantinib or immune checkpoint inhibitors including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy except in Expansion Cohorts 5, 7, 9, 11, 17, 19 and 20. Other restrictions regarding prior therapy may apply.
Known brain metastases or cranial epidural disease unless adequately treated and stable for at least 4 weeks before first dose of study treatment.
Concomitant anticoagulation with oral anticoagulants.
Subject is receiving systemic steroid therapy (>10 mg daily prednisone equivalent) or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.
Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
The subject has uncontrolled, significant intercurrent or recent illness, including, but not limited to, an active or history of autoimmune disease or immune deficiency; idiopathic pulmonary fibrosis, organizing pneumonia, pneumonitis; active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV), AIDS-related illness, acute or chronic hepatitis B or C infection, positive test for tuberculosis, moderate to severe hepatic impairment (Child-Pugh B or C).
Pregnant or lactating females.
Previously identified allergy or hypersensitivity to components of the study treatment formulations.
Diagnosis of another malignancy within 2 years before first dose of study treatment.
